CD276 and neoplasm: The medium-dose CD276 Dash CAR-T group had no tumor recurrence until the end of the trial (our experiment end on the day 115 after the treatment), and the low-dose Dash CAR-T group had slow tumor growth in some mice on day 91 after administration.